Johnson & Johnson posts strong third-quarter results and boosts guidance on the same day it announces a pause in its Covid-19 vaccine trial.
Johnson & Johnson posts strong third-quarter results and boosts guidance on the same day it announces a pause in its Covid-19 vaccine trial.
Wall Street lost ground on Tuesday, with halted COVID-19 vaccine trials and an elusive U.S. stimulus agreement weighing on..